KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Fulgent Genetics (FLGT) EBIAT (2016 - 2025)

Fulgent Genetics' EBIAT history spans 11 years, with the latest figure at -$22.5 million for Q4 2025.

  • For Q4 2025, EBIAT fell 261.32% year-over-year to -$22.5 million; the TTM value through Dec 2025 reached -$61.2 million, down 39.62%, while the annual FY2025 figure was -$60.5 million, 38.09% down from the prior year.
  • EBIAT for Q4 2025 was -$22.5 million at Fulgent Genetics, down from -$7.5 million in the prior quarter.
  • Across five years, EBIAT topped out at $200.7 million in Q1 2021 and bottomed at -$128.1 million in Q4 2023.
  • The 5-year median for EBIAT is -$10.3 million (2023), against an average of $18.8 million.
  • The largest annual shift saw EBIAT soared 10360.28% in 2021 before it crashed 1011.17% in 2023.
  • A 5-year view of EBIAT shows it stood at $104.3 million in 2021, then tumbled by 122.84% to -$23.8 million in 2022, then plummeted by 437.72% to -$128.1 million in 2023, then surged by 95.13% to -$6.2 million in 2024, then tumbled by 261.32% to -$22.5 million in 2025.
  • Per Business Quant, the three most recent readings for FLGT's EBIAT are -$22.5 million (Q4 2025), -$7.5 million (Q3 2025), and -$19.3 million (Q2 2025).